Navigation Links
TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
Date:4/2/2009

two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.tptxinc.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the ability for TorreyPines to complete a strategic transaction, including a possible sale of the Company. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2008 and TorreyPines other SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TorreyPines undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company Contact:
    Paul Schneider
    TorreyPines Therapeutics, Inc.
    858-623-5665, x125
    pschneider@TPTXinc.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
2. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
3. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
4. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
5. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
6. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
7. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
8. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
9. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
10. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
11. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... SAO PAULO , June 2, 2015   ... leader in biosimilars, today announced that its partner, Celltrion – ... ANVISA – the National Health Surveillance Agency in ... first biosimilar monoclonal antibody approved for use in ... by Hospira. Hospira also markets and sells biosimilar infliximab ...
(Date:6/2/2015)... LOUIS , June 2, 2015   ... Life Science and Technology company, announced today it ... Science to launch genetically engineered human neural ... advance the research of neurological diseases. These new ... provide unique and versatile tools for the study ...
(Date:6/2/2015)... June 02, 2015 Through rare discovery ... Yancy Corporation is enabling World Scientists to ... and biological sample, displaying the full nature (position, shape, ... atoms. , Jeff Porter, Co-Founder of the Yancy Corporation, ... that – rare. They come once in a lifetime, ...
(Date:6/1/2015)... June 1, 2015  Turing Pharmaceuticals AG announced that ... Salinas , MD, MSc,  has joined the company ... Dr. Salinas, who holds a medical degree as ... record of significant accomplishments in the pharmaceutical industry, ... Dr. Salinas has played a leadership role in ...
Breaking Biology Technology:ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 3Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3
... university researchers, aided by scientists at the National ... in integrating a new, highly efficient piezoelectric material ... could lead to significant advances in sensing, imaging ... as quartz, expands slightly when fed electricity and, ...
... /PRNewswire/ -- Radius Health, Inc. ("Radius") announced ... three-tranche $91 million financing round announced in May 2011. ... equity financing from Radius, current investors and $6.25 million ... and Oxford Finance LLC, bringing gross proceeds received to ...
... hole would prevent light from going through it, but Princeton University ... has found that placing a metal cap over a small hole ... but rather enhances its transmission. In an example of the ... electrical engineer Stephen Chou and colleagues made an array ...
Cached Biology Technology:Tiny levers, big moves in piezoelectric sensors 2Radius Closes $27.65 Million Second Tranche of Previously Announced Financing 2Radius Closes $27.65 Million Second Tranche of Previously Announced Financing 3Blocked holes can enhance rather than stop light going through 2Blocked holes can enhance rather than stop light going through 3
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS ... had a strong showing at AUVSI,s Unmanned 2015 ... representatives of Ohio,s UAS industry met ... abroad from all points along the UAS ecosystem. ... Coalition,s (DDC) Vice President for Aerospace Rich Knoll . ...
(Date:5/7/2015)... 7, 2015 Fingerprint Cards ... and FPC1035, FPC,s smallest touch fingerprint sensors to ... considered for integration on the backside of the ... increased possibilities to integrate touch fingerprint sensors in ... improves possibilities for module manufacturers to customize the ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... Although Antarctic krill (Euphausia superba) are one of the ... their life cycle have remained murky. , Understanding krill ... birds, and marine mammals, yet they are vulnerable to ... issue of BioScience, the monthly journal of the American ...
... Division of Cellegy Pharmaceuticals, Inc. today announced a non-exclusive ... the prevention of HIV and other sexually transmitted diseases. ... the agreement are in various stages of development and ... Savvy, which is currently in Phase III clinical trials ...
... five percent of deaths from SIDS (sudden infant death syndrome) ... gene and half of those deaths result from a common ... abnormal heart rhythm during times of environmental stress, a research ... February 2006 issue of the Journal of Clinical Investigation. ...
Cached Biology News:New licensing agreement to maximize AIDS drug development 2Gene variation increases SIDS risk in African Americans 2Gene variation increases SIDS risk in African Americans 3
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
... data analysis , Automatic grid, subgrid and spot ... template assignment , ... Extensive background and signal options to optimize, ... results , Characterize ...
... Agarose and SYBR Safe DNA Gel Stain combo offers ... versus buying these same products separately ... ethidium bromide Eliminates risks ... DNA and RNA fragments from 100 bp to >30 ...
... glycerol stocks contained in standard 96-well microtiter ... with approximately 5,000 clones per plate. After ... well, the corresponding subplate is screened with ... positive well(s). Cells from a positive well ...
Biology Products: